莱斯康制药(LXRX)
icon
搜索文档
Lexicon Pharmaceuticals(LXRX) - 2024 Q3 - Earnings Call Presentation
2024-11-13 09:39
3Q24 Earnings Presentation ‹#› Forward-Looking Statements • This presentation, including any oral presentation accompanying it, contains "forward-looking statements," including statements about Lexicon's strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as projections of our future results of operations or of our financial condition, the potential therapeutic and commercial potential of INPEFA® (sotagliflozin), ZYNQUISTA™ (sotagliflozin ...
Lexicon Pharmaceuticals(LXRX) - 2024 Q3 - Earnings Call Transcript
2024-11-13 09:39
Start Time: 17:00 January 1, 0000 5:55 PM ET Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2024 Earnings Call November 12, 2024, 17:00 PM ET Company Participants Mike Exton - CEO and Director Tom Garner - SVP and Chief Commercial Officer Craig Granowitz - SVP and Chief Medical Officer Alan Main - EVP, Innovation and Chemical Sciences Lisa DeFrancesco - Head, IR and Corporate Strategy Conference Call Participants Operator Good day, and welcome to the Lexicon Pharmaceuticals Third Quarter 2024 Results Confer ...
Lexicon Pharmaceuticals(LXRX) - 2024 Q3 - Quarterly Results
2024-11-13 05:06
Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA™ FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 2024 Concluded Enrollment Screening For Phase 2b PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP); Topline Data Expected in Q1 2025 Executed Repositioning of INPEFA (sotagliflozin ...
Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease
GlobeNewswire News Room· 2024-11-06 05:05
People with T1D and CKD treated with sotagliflozin and insulin had similar lowering effects on glycated hemoglobin (HbA1c), the primary endpoint, as people with T1D who do not have CKD Sotagliflozin was associated with a lower to neutral risk of severe hypoglycemia and did not significantly increase the risk of diabetic ketoacidosis (DKA) among a small number of DKA events THE WOODLANDS, Texas, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the peer-reviewed J ...
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
GlobeNewswire News Room· 2024-11-01 06:54
THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the outcome of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting to review the company’s New Drug Application (NDA) for Zynquista (sotagliflozin), an oral SGLT1/SGLT2 inhibitor, as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD). The Advisory Committee voted ...
Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer
GlobeNewswire News Room· 2024-09-16 20:00
THE WOODLANDS, Texas, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeff Wade, president and chief operating officer, has decided to step down to pursue new opportunities outside of Lexicon, effective September 30, 2024. A search for a new chief financial officer is ongoing. For the past 25 years, Mr. Wade has served in a series of finance, corporate development, administrative and legal leadership positions at Lexicon, serving most recently as presiden ...
New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
GlobeNewswire News Room· 2024-09-10 20:00
Study results aligned with positive clinical trial outcomes for type 1 diabetes treatment with sotagliflozin TIR measures approach target set by American Diabetes Association Data to be presented at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain and online THE WOODLANDS, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from the SOTA-INS CGM Phase 3 randomized clinical trial demonstrated tha ...
Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences
GlobeNewswire News Room· 2024-09-04 04:00
THE WOODLANDS, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lexicon management will participate in the following investor conferences taking place in September: H.C. Wainwright 26th Annual Global Investment Conference – Tuesday, September 10, 2024 at 12:30pm ET 2024 Cantor Fitzgerald Global Healthcare Conference – Tuesday, September 17, 2024 at 8:35am ET A simultaneous webcast for these events will be available in the "Events" section of the Lex ...
Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista
ZACKS· 2024-08-23 00:30
Lexicon Pharmaceuticals, Inc. (LXRX) announced that the FDA plans to hold an advisory panel meeting to give a recommendation on whether to approve Zynquista (sotagliflozin), which has been developed as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease (CKD). The meeting of the Endocrinologic and Metabolic Drugs Advisory Committee is scheduled to be held on Oct 31, 2024. However, despite scheduling an advisory committee meeting, the FDA did not chang ...
Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up
ZACKS· 2024-08-15 01:35
Lexicon Pharmaceuticals, Inc. (LXRX) announced a strategic review, including the reprioritization of its current portfolio of marketed products and pipeline candidates and reducing operational expenses, to drive future business growth. As part of the portfolio reprioritization, LXRX is looking to reduce its current headcount by almost 50%, which is likely to be completed later in the ongoing quarter. Owing to this, the company expects to reduce its operating costs by $40 million in 2025. The company also re ...